Evidence map›Paper›PMID 39587707›Full record

ArticleCancer medicine2024

Fusobacterium nucleatum Abundance is Associated with Cachexia in Colorectal Cancer Patients: The ColoCare Study.

Mmadili N Ilozumba, Tengda Lin, Sheetal Hardikar, Doratha A Byrd, June L Round, W Zac Stephens, Andreana N Holowatyj, Christy A Warby, Victoria Damerell, Christopher I Li and 11 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mmadili N IlozumbaHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Tengda LinHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Sheetal HardikarHuntsman Cancer Institute, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0003-0292-6168
Doratha A ByrdH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
June L RoundHuntsman Cancer Institute, Salt Lake City, Utah, USA.
W Zac StephensHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Andreana N HolowatyjHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Christy A WarbyHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Victoria DamerellDepartment of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Christopher I LiFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID https://orcid.org/0000-0003-1543-0743
Jane C FigueiredoDepartment of Medicine, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA.
Adetunji T ToriolaWashington University School of Medicine in St. Louis, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0003-1079-2606
David ShibataDepartment of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Gary C FillmoreHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Bartley PickronHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Erin M SiegelH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Christoph KahlertDepartment of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Vaia FlorouHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Biljana GigicDepartment of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Jennifer OseHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Cornelia M UlrichHuntsman Cancer Institute, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0001-7641-059X

Funding

Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer linkR01CA254108 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HURSTING, STEPHEN D, ULRICH, CORNELIA M · 2021 to 2025
$3.2M
Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancerR01AG083580 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheetal Hardikar · 2024 to 2026
$2.3M
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP StudyR01CA211705 · NCI · UNIVERSITY OF UTAH · PI LASTAYO, PAUL C, ULRICH, CORNELIA M · 2017 to 2021
$2.2M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
Cancer Control and Population Health Sciences (CCPS) at the University of UtahERA-NET (European Research Area Network) on Translational Cancer Research (TRANSCAN) projectGerman Cancer Research CenterHuntsman Cancer FoundationNCI NIH HHS K07 CA222060NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA211705NCI NIH HHS R01 CA254108NCI NIH HHS U01 CA206110NIA NIH HHS R01 AG083580Stiftung LebensBlicke, Matthias Lackas Stiftung, Claussen-Simon Stiftungthe German Consortium of Translational Cancer Research, (DKTK)the German Ministry of Education and Research project PerMiCCion (01KD2101D)the Rahel-Goitein-Straus-Program, Medical Faculty Heidelberg UniversityUniversity of Utah Immunology, Inflammation, and Infectious Disease Initiative
6 · The paper itself

Abstract

backgroundCachexia accounts for about 20% of all cancer-related deaths and indicates poor prognosis. The impact of Fusobacterium nucleatum (Fn), a microbial risk factor for colorectal cancer (CRC), on the development of cachexia in CRC has not been established.

methodsWe evaluated the association between Fn abundance in pre-surgical stool samples and onset of cachexia at 6 months post-surgery in n = 87 patients with stages I-III CRC in the ColoCare Study.

resultsHigh fecal Fn abundance compared to negative/low fecal Fn abundance was associated with 4-fold increased risk of cachexia onset at 6 months post-surgery (OR = 4.82, 95% CI = 1.15, 20.10, p = 0.03).

conclusionOur findings suggest that high fecal Fn abundance was associated with an increased risk of cachexia at 6 months post-surgery in CRC patients. This is the first study to link Fn abundance with cachexia in CRC patients, offering novel insights into biological mechanisms and potential management of cancer cachexia. Due to the small sample size, our results should be interpreted with caution. Future studies with larger sample sizes are needed to validate these findings.

Indexed as

CachexiaColorectal NeoplasmsFecesFusobacterium nucleatumAgedFemaleFusobacterium InfectionsHumansMaleMiddle AgedNeoplasm StagingRisk Factorscachexiacolorectal cancerFusobacterium nucleatum

Identifiers

PMID39587707
PMCPMC11588854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.